Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment.